MYC expression
|
Diffuse Large B Cell Lymphoma
|
MYC expression
|
Diffuse Large B Cell Lymphoma
|
RG6146 Sensitive: C2 – Inclusion Criteria
|
RG6146 Sensitive: C2 – Inclusion Criteria
|
MYC expression
|
Triple Negative Breast Cancer
|
MYC expression
|
Triple Negative Breast Cancer
|
pembrolizumab + MK-7965 Sensitive: C3 – Early Trials
|
pembrolizumab + MK-7965 Sensitive: C3 – Early Trials
|
MYC expression
|
Medulloblastoma
|
MYC expression
|
Medulloblastoma
|
JHU395 Sensitive: D – Preclinical
|
JHU395 Sensitive: D – Preclinical
|
MYC expression
|
Multiple Myeloma
|
MYC expression
|
Multiple Myeloma
|
JQ-1 Sensitive: D – Preclinical
|
JQ-1 Sensitive: D – Preclinical
|
MYC expression
|
Multiple Myeloma
|
MYC expression
|
Multiple Myeloma
|
lenalidomide + CCS1477 Sensitive: D – Preclinical
|
lenalidomide + CCS1477 Sensitive: D – Preclinical
|
MYC expression
|
AML
|
MYC expression
|
AML
|
CCS1477 Sensitive: D – Preclinical
|
CCS1477 Sensitive: D – Preclinical
|
MYC expression
|
Small Cell Lung Cancer
|
MYC expression
|
Small Cell Lung Cancer
|
AZD2811 Sensitive: D – Preclinical
|
AZD2811 Sensitive: D – Preclinical
|
MYC expression
|
Ovarian Cancer
|
MYC expression
|
Ovarian Cancer
|
KB-0742 Sensitive: D – Preclinical
|
KB-0742 Sensitive: D – Preclinical
|